Persistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.

TitlePersistent alveolar type 2 dysfunction and lung structural derangement in post-acute COVID-19.
Publication TypeJournal Article
Year of Publication2022
AuthorsRendeiro AF, Ravichandran H, Kim J, Borczuk AC, Elemento O, Schwartz RE
JournalmedRxiv
Date Published2022 Nov 29
Abstract

SARS-CoV-2 infection can manifest as a wide range of respiratory and systemic symptoms well after the acute phase of infection in over 50% of patients. Key questions remain on the long-term effects of infection on tissue pathology in recovered COVID-19 patients. To address these questions we performed multiplexed imaging of post-mortem lung tissue from 12 individuals who died post-acute COVID-19 (PC) and compare them to lung tissue from patients who died during the acute phase of COVID-19, or patients who died with idiopathic pulmonary fibrosis (IPF), and otherwise healthy lung tissue. We find evidence of viral presence in the lung up to 359 days after the acute phase of disease, including in patients with negative nasopharyngeal swab tests. The lung of PC patients are characterized by the accumulation of senescent alveolar type 2 cells, fibrosis with hypervascularization of peribronchial areas and alveolar septa, as the most pronounced pathophysiological features. At the cellular level, lung disease of PC patients, while distinct, shares pathological features with the chronic pulmonary disease of IPF. which may help rationalize interventions for PC patients. Altogether, this study provides an important foundation for the understanding of the long-term effects of SARS-CoV-2 pulmonary infection at the microanatomical, cellular, and molecular level.

DOI10.1101/2022.11.28.22282811
Alternate JournalmedRxiv
PubMed ID36482970
PubMed Central IDPMC9727772
Grant ListT32 CA203702 / CA / NCI NIH HHS / United States
R01 CA194547 / CA / NCI NIH HHS / United States
UL1 TR002384 / TR / NCATS NIH HHS / United States
R01 DK121072 / DK / NIDDK NIH HHS / United States
R01 AI107301 / AI / NIAID NIH HHS / United States